<DOC>
	<DOCNO>NCT01546324</DOCNO>
	<brief_summary>The purpose study collect blood sample pregnant woman achieve pregnancy follow in-vitro fertilization ( IVF ) Natera 's preimplantation aneuploidy screening ( without single gene gene test ) . These sample use test development non-invasive prenatal diagnostic testing .</brief_summary>
	<brief_title>Collection Maternal Blood Samples Development Non-invasive Prenatal Diagnostic Testing</brief_title>
	<detailed_description>Eligible subject sign consent form blood drawn approximately 8-17 week gestation . Subjects receive $ 200 reimbursement provide blood sample . The collected sample use help develop non-invasive prenatal diagnostic test use Natera 's Parental Support technology already commercialize genetic diagnosis in-vitro embryo . In study , technology test 's ability analyze fetal-specific piece DNA isolate mother 's blood . No result maternal blood test report subject physician .</detailed_description>
	<criteria>Pregnant woman willing donate blood sample first second trimester pregnancy ( approximately 817 week gestation ) Use Natera ( formerly Gene Security Network ) 's commercial preimplantation genetic testing ( PGS/PGD ) achieve current pregnancy Pregnant woman use Natera ( formerly Gene Security Network ) 's PGS/PGD test achieve current pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Maternal Blood</keyword>
	<keyword>PGD</keyword>
	<keyword>PGS</keyword>
	<keyword>Natera</keyword>
	<keyword>Gene Security Network</keyword>
	<keyword>Non-invasive prenatal diagnosis</keyword>
</DOC>